Introduction {#Sec1}
============

Bone metastases are a common manifestation of malignancy that can cause severe and debilitating effects, including pain, spinal cord compression, hypercalcemia, and pathologic fractures. The proper care of patients with bone metastasis requires interdisciplinary treatment delivered by orthopedic surgeons, radiation oncologists, medical oncologists, pain medicine specialists, radiologists, and palliative care professionals. Radiotherapy (RT) can provide successful palliation of painful bone metastasis in 50--80 % of patients in a time efficient manner, and is associated with very few adverse effects, allowing complete pain relief at the treated site in up to one-third of patients \[[@CR1]\]. Recently, in the field of radiation oncology, emerging novel techniques have been developed and adapted for the treatment of bone metastases. In light of these advances, the focus of this review includes the efficacy of RT, new RT methods, and relevant prognostic factors. The significance of each of these in the management of spinal bone metastases is discussed.

Radiation dose and schedule {#Sec2}
===========================

RT is commonly used to provide pain relief in cases of painful bone metastases. Chow et al. \[[@CR2]\] conducted a meta-analysis of 25 randomized palliative RT trials for uncomplicated painful bone metastases comparing 8 Gy in single and 20--30 Gy in multiple fractions. They concluded that both the overall pain relief rate (60 % in the single-fraction arm and 61 % in the multiple-fraction arm) and the complete pain relief rate (23 and 24 %, respectively) were similar with no significant difference between these schedules. Although retreatment rates were higher in those who received single-fraction therapy, 8 Gy in single-fraction RT was suggested as the standard of care for the palliation of uncomplicated painful bone metastases in the recent American Society for Therapeutic Radiology and Oncology guidelines \[[@CR3]\].

It is possible that patients with metastatic spinal cord compression (MSCC) will benefit more from higher-dose multiple-fraction RT than they would from lower-dose single-fraction RT, although currently, there is little data to support this (Table [1](#Tab1){ref-type="table"}). In their review, Chow et al. \[[@CR1]\] found that spinal cord compression occurred in 5.7 and 4.1 % of patients who received single-fraction and multiple-fraction RT, respectively. Although there was a trend favoring multiple-fraction RT, this did not reach statistical significance (*P* = 0.31). Rades et al. \[[@CR4]\] evaluated the local control achieved using different RT schedules for MSCC. In their prospective, non-randomized study, local control was found to be significantly better after a long course of treatment (30 Gy in 10 fractions, 37.5 Gy in 15 fractions, and 40 Gy in 20 fractions) compared to a shorter course (8 Gy in a single-fraction, and 20 Gy in 4 fractions). In contrast, Maranzano et al. \[[@CR5]\] demonstrated that a single-fraction RT was sufficient, and resulted in only minimal toxicity for patients with a poor prognosis.Table 1Outcomes of conventional RT for MSCCReferencesStudy designState of diseaseDoseAmbulatory rate before treatment (%)Motor function improvement (%)LCOverall survivalMaranzano \[[@CR5]\]RCTUnfavorable prognosis8 Gy/1 Fr6412NA4 months (median)16 Gy/2 Fr6721NA4 months (median)Rades \[[@CR4]\]Prospective non-RCTVarious8 Gy/1 Fr, 20 Gy/4 Fr613761 % at 1 years23 % at 1 year30--40 Gy/10--20 Fr623981 % at 1 years30 % at 1 yearRades \[[@CR7]\]Matched cohortFavorable prognosis30 Gy/10 Fr854071 % at 2 years53 % at 2 years37.5 Gy/15 Fr 40 Gy/20 Fr854192 % at 2 years68 % at 2 yearsRades \[[@CR6]\]RetrospectiveRadio-resistant tumor30 Gy/10 Fr621876 % at 1 yearNA37.5 Gy/15 Fr 40 Gy/20 Fr632280 % at 1 yearNA*RT* radiotherapy, *MSCC* metastatic spinal cord compression, *LC* local control, *RCT* randomized controlled trial, *Fr* fraction, *NA* not available

Rades et al. \[[@CR6]\] suggested in their retrospective study that dose escalation beyond 30 Gy in 10 fractions did not improve motor function and local control of MSCC in radioresistant tumors, such as renal cell carcinoma, colorectal cancer, and malignant melanoma. However, in another report \[[@CR7]\], dose escalation beyond 30 Gy was found to give better local control and extend overall survival in patients with breast cancer, prostate cancer, myeloma/lymphoma, and others who had a favorable prognosis. Thus, 30 Gy in 10 fractions could be regarded as the standard therapeutic dose for MSCC. Although the available evidence is limited, dose escalation beyond 30 Gy may improve local control and overall survival in patients with a favorable survival prognosis, but it may not improve functional outcome, and dose escalation to 40 Gy in 20 fractions may still be insufficient for radioresistant tumors.

IMRT and stereotactic body RT {#Sec3}
=============================

Recently, two sophisticated RT techniques, stereotactic body RT (SBRT; including stereotactic radiosurgery and stereotactic RT) and intensity-modulated RT (IMRT) have been adapted for the treatment of spinal bone metastases. SBRT uses more beams from many more directions than conventional opposed-field RT and consequently delivers much higher doses in a hypofractionated manner (either as a single fraction or as a smaller number of fractions). IMRT makes it possible to deliver optimal radiation doses safely to an irregularly shaped target while minimizing the dose to the surrounding normal structures. In order to achieve a high standard of targeting precision, these approaches require that the exact location and shape of the tumor be determined using imaging techniques (Fig. [1](#Fig1){ref-type="fig"}). In general, the term "spinal SBRT" refers to the use of both IMRT techniques and SBRT. The most important additional benefit of spinal SBRT is the possibility of achieving excellent dose coverage of the target, while avoiding the spinal cord, which is often the major limiting factor when delivering high-dose RT (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}). Multiple retrospective studies have demonstrated that SBRT could feasibly be used to treat spinal metastases, and could control target lesions with only low toxicity \[[@CR8], [@CR9]\]. The local control rate based on imaging and/or pain management criteria was reported to be greater than 80 %, with only rare cases of toxicity.Fig. 1*Upper* *panels* the CyberKnife apparatus (*left*); a 3-dimensional rendered image (*right*) *blue lines* indicate beam directions. *Lower* *panels* Xsight, the image-guidance system used in the CyberKnife system, enables the automatic tracking of skeletal structures (*left*). Representative dose distribution (*right*)Fig. 2Comparison of radiation dose distributions between conventional radiotherapy (*left*) and intensity-modulated radiotherapy (*right*). Each *colored line* indicates an *isodose curve*. A higher radiation dose is concentrated on the vertebral bone metastasis while avoiding the heart and lungs (*right*)

The indication and appropriateness of SBRT in the treatment of spinal bone metastases should be carefully considered. The published efficacy and safety data for SBRT have mostly been from retrospective, single institution studies. Neither the exact dosing and target delineation requirements, nor the most appropriate inclusion and exclusion criteria for SBRT have been fully defined. In most previous studies of spinal SBRT, the primary endpoint for efficacy was the local control rate based on imaging and/or pain control, while motor function and ambulatory status were rarely considered. In their guidelines for RT of bone metastasis, Lutz et al. \[[@CR3]\] suggested that SBRT might be useful for treating spinal bone metastases, although they also advised that this should preferably be within the confines of a clinical trial.

Postoperative irradiation {#Sec4}
=========================

Surgery plays an important role in the management of patients with symptomatic MSCC. For patients with severe MSCC, Patchell et al. \[[@CR10]\] demonstrated that surgical decompression was beneficial in the only randomized, multi-institutional trial to date. Significantly more patients who underwent surgery plus postoperative RT regained the ability to walk compared to those who only received RT. Patients treated with surgery also retained the ability to walk significantly longer than those treated with RT alone. Moreover, surgery only restored the ability to walk in 30 % of patients who failed to respond to earlier RT, which compares unfavorably with the 62 % post-treatment ambulatory rate of the patients who were originally not able to walk and received surgery as their first treatment. Based on these findings, the authors claimed that surgery plus RT was the best first-line treatment for MSCC. However, this result conflicts with the findings of Rades et al. \[[@CR11]\], who showed that surgery plus RT for MSCC patients with various primary tumors did not significantly improve their functional outcome compared to RT alone. They also showed that surgery was beneficial for patients with relatively radioresistant primary tumors \[[@CR12]\] (Table [2](#Tab2){ref-type="table"}).Table 2Outcome of conventional RT with or without surgery for MSCCReferencesStudy designType of primary tumorSurgeryDoseAmbulatory rate before treatment (%)Ambulatory rate after treatment (%)Regained ability to walk (%)LCOverall survivalPatchell \[[@CR10]\]RCTExcluded highly radiosensitive tumorsSurgery + RT30 Gy/10 Fr688462NA126 days (median)RT30 Gy/10 Fr695719NA100 days (median)Rades \[[@CR11]\]Matched cohortVariousSurgery + RT30--40 Gy/10--20 Fr63693090 % at 1 year47 % at 1 yearRT30--40 Gy/10--20 Fr63682691 % at 1 year40 % at 1 yearRades \[[@CR12]\]Matched cohortUnfavorable^a^Surgery + RT30--40 Gy/10--20 Fr64672985 % at 1 year38 % at 1 yearRT30--40 Gy/10--20 Fr64611989 % at 1 year24 % at 1 year*RT* radiotherapy, *MSCC* metastatic spinal cord compression, *LC* local control, *RCT* randomized controlled trial, *Fr* fraction, *NA* not available^a^Non-small cell lung cancer, unknown primary cancer, renal cell carcinoma, and colorectal cancer

Although the exact criteria for surgery in MSCC patients continue to be debated, the following are generally agreed to be necessary: a favorable survival prognosis, a good performance status, a relatively radioresistant tumor type, and MSCC accompanied with mechanical instability \[[@CR13], [@CR14]\]. RT alone is recommended for MSCC from highly radiosensitive tumors, such as hematological malignancies and germ cell tumors. A dose of 30 Gy in 10 fractions for MSCC in a postoperative setting is the most frequently used and is now considered to be the standard treatment \[[@CR10]--[@CR12]\]. Higher doses may also be administered to patients with a favorable prognosis. However, these doses are based on the use of RT alone for MSCC, and there are no reports comparing optimal postoperative RT doses.

A number of retrospective reports have focused on the postoperative efficacy of SBRT in MSCC patients (Table [3](#Tab3){ref-type="table"}). The study with the largest cohort, by Laufer et al. \[[@CR16]\], reported that high-dose hypofractionated SBRT provided better local tumor control compared with low-dose hypofractionated SBRT. Epidural disease is one of the major factors limiting the efficacy of spinal SBRT. Al-Omair et al. \[[@CR17]\] showed that epidural disease progression was the most common treatment failure after spinal SBRT, and postoperative epidural disease grade was a significant predictor of local control. Ideally, in order to administer a tumoricidal radiation dose by SBRT more safely, it may be possible to create a small margin of 2--3 mm between the tumor and the spinal cord by performing separation surgery. This allows a full dose to be administered to the entire tumor volume while minimizing the radiation exposure to the spinal cord. A treatment approach reported by Bate et al. \[[@CR18]\] that included SBRT alone for patients with minimal MSCC, and separation surgery followed by SBRT for patients with high-grade MSCC, seems a reasonable strategy.Table 3Outcomes of postoperative SBRT or SBRT alone for MSCCReferencesPatients/lesionsRe-RTTreatmentDoseNeurological responsePostop MSCCLC at 1 yearRyu \[[@CR15]\]62/850SBRT alone12--20 Gy/1 FrRemained intact in 94 %, improved in 52 %, stable in 11 %, progression in 16 %NANALaufer \[[@CR16]\]1860Surgery + SBRTNA11 %83.6 %1097518--36 Gy/5--6 Fr77.4 %371424--30 Gy/3 Fr95.9 %40224 Gy/1 Fr91 %Al-Omair \[[@CR17]\]800Surgery + SBRTNA10 %84 %35018--26 Gy/1--2 Fr100 %45018--40 Gy/3--5 Fr70 %Bate \[[@CR18]\]57/690NA94.2 %21 lesions6Surgery + SBRT16--23 Gy/1 Fr, 20--30 Gy/3--5 FrFrankel score improved in 14 %, stable in 81 %, and declined in 5 %90.5 %48 lesions24SBRT alone16--23 Gy/1 Fr 20--30 Gy/3--5 FrFrankel score improved in 10 %, and stable in 90 %95.8 %*SBRT* stereotactic body radiotherapy, *MSCC* metastatic spinal cord compression, *LC* local control, *Fr* fraction, *NA* not available

Re-irradiation of spinal bone metastases {#Sec5}
========================================

Notably, re-irradiation is effective in improving or maintaining motor function. Rades et al. \[[@CR19]\] conducted a retrospective study of re-irradiation for MSCC, and found that motor function improved in 36 % of patients, was stable in another 50 % of patients, and deteriorated in 14 % of patients, and that there were no cases of late toxicity, such as radiation myelopathy. The degree of motor function after re-irradiation was associated with the effectiveness of the initial RT, performance status, time to development of motor deficits, and visceral metastases, whereas the re-irradiation schedule had no significant impact. A recent multicenter, randomized trial \[[@CR20]\] of re-irradiation for painful bone metastases, of which 28 % were in the spine, showed that treatment with 8 Gy in a single fraction was as effective as, and less toxic than 20 Gy in multiple fractions; however, these findings were not robust in per-protocol analysis.

SBRT is well suited for re-irradiation of the spine and may provide superior tumor control compared to conventional techniques, with reported local control rates of 66--93 % \[[@CR21]--[@CR23]\] (Table [4](#Tab4){ref-type="table"}). Several studies identified potential risk factors for local recurrence after re-irradiation by spinal SBRT. Garg et al. \[[@CR21]\] reported in their prospective study of spinal re-irradiation by SBRT that 13 of 16 patients with local progression after SBRT had tumors within 5 mm of the spinal cord, and 6 of them eventually developed MSCC. Damast et al. \[[@CR22]\] studied the dose--response with SBRT used for re-irradiation, and found that there were significantly fewer local failures after SBRT with 30 Gy in 5 fractions compared to 20 Gy in 5 fractions.Table 4Outcomes of re-irradiation by spinal SBRTReferencesPatients/lesionsEpidural diseaseDoseNeurological responseMSCC after re-RTLCOverall survivalNo neurologic deteriorationNeural toxicityOther toxicityGarg \[[@CR21]\]59/63None30 Gy/5 Fr 27 Gy/3 FrNA1 %76 % at 1 year76 % at 1 year92 % at 1 year2 of G3 radiculopathyNoneMahadevan \[[@CR23]\]60/8127 %24 Gy/3 Fr 25--30 Gy/5 FrRadiculopathy improved 11 of 14, lower-limb weakness was stable 4 of 4NA93 % at last follow-up11 months (median)NA3 Cases of radicular pain and 1 of lower-extremity weakness with tumor progressionNoneDamast \[[@CR22]\]95/9748 % Postop RTNANA66 %13.6 months (median)NANone9 VCF, 1 esophageal stricture42/4220 Gy/5 Fr55 % at 1 year53/5530 Gy/5 Fr74 % at 1 year*SBRT* stereotactic body radiotherapy, *MSCC* metastatic spinal cord compression, *LC* local control, *Fr* fraction, *VCF* vertebral compression fracture, *NA* not available

Relatively little is known regarding the long-term toxicities of re-irradiation. Because re-irradiation has the potential to exceed normal tissue tolerance, care must be taken when the re-irradiated volume contains the spinal cord, and it might be appropriate to sum the biologically effective doses (BEDs) from the initial and repeat treatment regimens in order to estimate the risk of radiation myelopathy \[[@CR3]\]. Radiation-induced myelopathy can occur 3--25 months after RT \[[@CR24], [@CR25]\], although complications associated with spinal re-irradiation are only rarely reported. Higher cumulative RT doses (BED \> 135.5 Gy~2~), higher doses of each RT course (BED \> 98 Gy~2~), and a short interval between the courses (\<6 months) could be associated with a higher probability of developing radiation-induced myelopathy \[[@CR24]\].

Assessment for spinal instability in the treatment of spinal bone metastases {#Sec6}
============================================================================

Spinal instability is associated with the development of neurologic deficits, mechanical pain, and progressive deformity \[[@CR26]\]. Therefore, early recognition of impending instability may prevent painful collapse and loss of function by prompting timely referral and treatment. In order to create a simple, standardized referral tool for non-spine specialists, the Spine Oncology Study Group developed the spinal instability neoplastic score (SINS) \[[@CR26]\], which is based on clinical and radiologic findings. Huisman et al. \[[@CR27]\] showed that a higher SINS increased the risk of RT failure in patients with spinal metastases, independent of the performance status, primary tumor type, and symptoms. They hypothesized that metastatic spinal bone pain, predominantly caused by mechanical instability, responds less well to RT than pain that results mainly from local tumor activity.

Vertebral fracture is common after RT for metastatic spine lesions (Fig. [3](#Fig3){ref-type="fig"}). Rose et al. \[[@CR28]\] demonstrated that lytic disease involving more than 40 % of the vertebral body and located at or below T10 confers a high risk of fracture, with correspondingly poorer clinical outcomes. Sahgal et al. \[[@CR29]\] reported the results of the first multi-institutional study of SBRT-induced vertebral compression fractures (VCFs), including whether the SINS can predict this adverse event. The crude risk of fracture was 14 %, the median time to VCF was 2.5 months, and the majority (65 %) of VCFs occurred in the first 4 months following SBRT. Moreover, multivariable analysis identified dose per fraction (greatest risk for ≥20 Gy), in addition to 3 of the 6 original SINS criteria: baseline VCF, a lytic tumor, and spinal deformity, as significant predictors of VCF. In a review of SBRT-induced VCF, 11--47 % of patients who developed VCFs needed a salvage spinal reconstruction procedure, such as percutaneous cement augmentation procedures or open spinal reconstructive surgery \[[@CR30]\]. These results may help clinicians identify high-risk patients who would benefit from prophylactic vertebro- or kyphoplasty.Fig. 3Radiographs of a patient with thoracic spinal bone metastasis from breast cancer. Vertebral compression fracture deterioration at 3 months (**c**) compared to that at 1 month (**b**) after conventional radiotherapy (**a**). The patient was successfully treated via posterior stabilization (**d**)

Conclusion {#Sec7}
==========

RT is typically the mainstay of treatment for spinal bone metastases. A number of studies have shown that palliative RT can be effective for painful bone metastases, while relatively little is known about the management of spinal bone metastases, especially MSCC. The management of MSCC requires a consideration of motor function and spinal instability as well as pain and local control. SBRT can safely administer a higher dose to the target, and can potentially provide lasting local control. SBRT is a promising method; however, epidural recurrence after SBRT and SBRT-induced VCF continue to be problematic, and require the appropriate application of combination SBRT and surgery. An evaluation of functional outcomes following spinal SBRT and the identification of indicators for surgery are needed to establish an optimal treatment strategy for spinal metastases.

This review article was presented at the 87th Annual Meeting of the Japanese Orthopaedic Association, Kobe, May 25th, 2014.

The authors thank Professor Masahiro Kurosaka for his encouragement. They also thank all the members of the Bone Meta Board conference, and Dr. H. Nishimura, Dr. H. Mayahara, and Dr. M. Fujii of the Kobe Minimally Invasive Cancer Center for their kind support regarding IMRT and CyberKnife treatment.

Conflict of interest {#d30e1499}
====================

None of the authors have any conflict of interest to declare.
